A pivotal trial is the primary evidence base for a PMA, De Novo, or PMA Supplement, and increasingly for high-risk MDR submissions. Endpoints are pre-specified, statistical analysis plans are locked, and the study is typically powered for the regulatory hypothesis. Pivotal trials are usually randomized or compared against performance goals, run under an approved IDE in the US, and agreed with FDA through the Q-Submission program before enrollment. Under the EU MDR, they are clinical investigations under Article 62 and Annex XV. Endpoint selection, sample size and analysis population choices are among the most common topics of regulator feedback.

Why it matters

Often preceded by feasibility and EFS studies and followed by post-approval/PMCF studies.

Common pitfalls

•A common pitfall is conducting a pivotal trial without first establishing a clear statistical analysis plan, which can lead to questions about data integrity and interpretation.
•Failing to adequately power a pivotal trial for its primary endpoints can result in inconclusive results, necessitating additional studies.
•Misinterpreting preliminary data from feasibility or early feasibility studies as sufficient for regulatory submission is a frequent mistake.
•Not addressing potential biases in patient selection or data collection during the trial design phase can undermine the validity of the results.
•Neglecting to consider the long-term follow-up requirements for certain devices can lead to incomplete data at the time of submission.

Sources

21 CFR Part 812, Investigational Device Exemptions · eCFR
ISO 14155 Standard Page · ISO
FDA - Clinical Trials and Human Subject Protection · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.